Moxifloxacin: An Alternative to Ethambutol for the Treatment of Presumed Ocular Tuberculosis. (Q41083720)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222893%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

title

Moxifloxacin: An Alternative to Ethambutol for the Treatment of Presumed Ocular Tuberculosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222893%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222893%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Rupesh Agrawal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222893%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Claire Barraclough

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222893%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Farzana Rahman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222893%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Mark Westcott

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222893%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Carlos E Pavesio

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222893%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Veronica White

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222893%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

29 July 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222893%20AND%20SRC:MED&resulttype=core&format=json

Ocular Immunology and Inflammation

20 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222893%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222893%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222893%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

508-514

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222893%20AND%20SRC:MED&resulttype=core&format=json

Intraocular tuberculosis--an update

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2015.1019155

The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2015.1019155

Incidence of ethambutol-related visual impairment during treatment of active tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2015.1019155

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2015.1019155

Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2015.1019155

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2015.1019155

Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2015.1019155

Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2015.1019155

Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2015.1019155

Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2015.1019155

Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2015.1019155

Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2015.1019155

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2015.1019155